3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Prostatic Neoplasms
3
Leukemia
2
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Stomatitis
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Carcinoma, Non-Small-Cell Lung
1
Astrocytoma
1
Adenocarcinoma
1
Interventions
Temozolomide
37
Radiotherapy
20
Bevacizumab
14
Carboplatin
10
Magnetic Resonance Spectroscopy
9
Carmustine
9
antineoplaston AS 2-1
8
antineoplaston A10
8
Irinotecan
8
Filgrastim
7
Cyclophosphamide
6
Cisplatin
6
Etoposide
5
sargramostim
4
Vincristine
4
Thiotepa
4
Surgical Procedures, Operative
4
Specimen Handling
4
Radiation
4
Peripheral Blood Stem Cell Transplantation
4
Lomustine
4
Everolimus
4
Chemotherapy, Adjuvant
4
trametinib
3
aldesleukin
3
Topotecan
3
Thalidomide
3
Tamoxifen
3
Sunitinib
3
Procarbazine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Astrocytoma
×
Valacyclovir
×
Clear all
NCT00589875
2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2
Completed
52 enrolled
10 charts